Martin Shkreli may be cooling his heels in a federal prison, but the pharma pricing strategy he pursued that got him into an intense national controversy appears to be alive and well in Europe this week.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,